Infectious Diseases Working Party (IDWP)
Study type:
Study number:
84140140
Type of treatment:
Allogeneic - Haploidentical
Diseases:
Short title:
ADV infections in hapoidentical transplanted patients
Primary objective:
1. To retrospectively evaluate the incidence of Adenovirus infection in patients transplanted with haploidentical SC either T cell ex-vivo depleted (manipulated, alfa/beta/CD19 or CD45RA depleted or other) or or with cyclophosphamide post-HSCT in centers that perform routine surveillance (2 times per week, 1 time per week, every 2 weeks) for adenovirus or research adenovirus according to patient’s symptoms or immune recovery
2. To compare the incidence of "clinically significant infection", "proven/probable disease" and "mortality adenovirus-related" in these different haploidentical transplant platforms
2. To compare the incidence of "clinically significant infection", "proven/probable disease" and "mortality adenovirus-related" in these different haploidentical transplant platforms
Key inclusion criteria:
- transplant received from 01/01/2015 to 31/12/2020 with an expected end of follow-up on 31/06/ 2021
- Adenovirus infection that occurred within 180 days following HSCT
- Adenovirus infection that occurred within 180 days following HSCT
Country:
Principal investigator:
Maura Faraci
EBMT Study coordinator:
Lotus Wendel
Study coordinator email:
idwp.ebmt@lumc.nl